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1. Introduction 
Bovine high molecular weight (HMW) kininogen is 
a monomeric plasma glycoprotein having a mol. wt. 
of about 76 000 [ 11. It consists of a single chain 
polypeptide with a masked N-terminal residue and 
C-terminal leucine and carries the vasoactive peptide, 
bradykinin, in the intrachain disulfide loop [2]. On 
incubation of this kininogen with plasma kallikrein, 
two major peptide fragments, in addition to the kinin, 
are liberated [3]. One of these fragments, fragment 2 
named tentatively histidine-rich peptide, has a biologi- 
cal activity which strongly inhibits the activation of 
Hageman Factor (Factor XII) by glass or kaolin [4,5]. 
Its amino acid sequence consisting of the total 41 
residues has been established [6]. The other peptide, 
named fragment 1, has been characterized to be a 
glycopeptide containing also high level of histidine 
[7]. During these studies, we found that above two 
fragments are not directly produced from the pre- 
cursor protein but a large fragment, named fragment 
1.2 is first liberated in parallel with the formation of 
bradykinin and subsequently cleaved by plasma 
kallikrein into fragment 1 (glycopeptide) and fragment 
2 [lo]. We describe here the complete amino acid 
sequence of fragment 1 and its location in HMW 
kininogen. 
2. Materials and methods 
HMW kininogen and prekallikrein were highly 
purified, respectively, from a fresh bovine plasma by 
North-Holland Publishing Company - Amsterdam 
the previous methods [ 1,8], and the latter was 
activated by purified prekallikrein activator (Factor 
XIIa) [9]. The specific activity of the kallikrein was 
23.5 TAME units per mg protein. A large fragment, 
fragment 1.2, was prepared according to the previous 
method [lo]. This large fragment (41 mg) was further 
incubated at 37°C for 80 min with 0.66 mg of the 
purified kallikrein in 8.0 ml of 0.2 M NH,,HCOJ, pH 
8.0, and the resulting digest was separated on a column 
of Sephadex G-75 (3.0 X 142 cm) in 0.2 M (NH,) 
HC03, pH 8.0. Two peptide fragments, fragment 1 
(28 mg) and fragment 2 (8.0 mg) were obtained. The 
sequence studies including tryptic and c+chymotryptic 
digestions, and peptide isolation, analysis and sequence 
determination were carried out as described pre- 
viously [6]. 
3. Results and discussion 
Fig. 1 shows the complete amino acid sequence of 
fragment 1 isolated from HMW kininogen. For the 
sequence analysis, direct Edman degradation was first 
performed and the partial N-terminal sequence up to 
12 residues was established. A large CNBr fragment 
isolated from whole fragment 1 was also used to 
determine the sequence of serine-21 to serine-30. 
Fragment 1 (1.6-2 pmole) was then digested, 
respectively, with TPCK-treated trypsin and cu-chymo- 
trypsin, and the resulting peptides were fractionated 
and purified. Much of sequence work was based on 
the eight major tryptic peptides, and the order of 
these and other aspects of the sequence were estab- 
197 
Volume 63, number 1 FEBS LETTERS March 1976 
I 5 IO 15 20 25 
PI0 
H-Ser-Vol-Gln-Val-MetCys-Thr-Glu-Gly-Ser-Thr-Thr-Val-S~r-~~~- Pro-Hls-Ser-Ala-Met-Ser-Pro-Vol-Gln-Asp- 
777777777777 CHO 77777 
t-- T-IV-I -+t T-l 
l 
30 35 40 45 50 
Glu-Glu-&~A~Ser-Gly-Lys-Glu-Gln-Gly-Pro-Th~His-Gly-His-Gly-Trp-~His-Gly-Lys-Gln-lIe-Lys-Leu- 
77777 
-C-T-V-I-+-T-III-I ) t T-V-2-+ t 
cs-2 ~+c9-2~-c4~ 
55 60 65 
His-Gly-Leu-Gly-Lau-Gly-Hls-Lys-His-Lys-Hls-Asp-Gln-Gly-His-Gly-His-His- 
fySs_OH 
Arg 
-T-III-2 - ~T-l~2++T-l~1-4. T-11-2,- 
+ C7-3--+tC5-20 + t------c3-4-------;, +c7-I+ 
Fig.1. Complete amino acid sequence of fragment 1 (glycopeptide) derived from bovine HMW kininogen. The peptides from 
digests with trypsin (T) and cu-chymotrypsin (C) are shown by arrows. Horizontal arrows pointing to the right and left below 
the amino acid residues denote that the sequences were determined by direct Edman degradation or the dansyl-Edman method 
[6] and selective tritium labeling, respectively [ 151. 
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Fig.2. Amino acid sequence of the C-terminal large portion following bradykinin moiety and the locations of fragment 1 and 
fragment 2 in bovine HMW kininogen. CHO represents a carbohydrate chain. Plasma kallikrein-sensitive bonds are shown by 
arrows. 
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lished by.seven major chymotryptic peptides and 
three CNBr peptides. Fragment 1 consisted of a total 
of 69 amino acid residues with N-terminal serine and 
C-terminal arginine (and lysine). It contained a single 
oligosaccharide chain consisting of galactosamine, 
galactose and sialic acid, which is probably linked 
with a serine residue at No. 14. Moreover, fragment 1 
contained a genetic variant, as indicated with the 
findings of amino acid substitutions at the positions 
of Thr-12 (Pro), Leu-15 (Val) and Arg-69 (Lys). The 
other interesting finding was that repeating sequence 
with the type of His-Gly-X appears five times in the 
C-terminal half of the fragment. This type of repeated 
structure had also been found in fragment 2 (histidine. 
rich peptide) [6]. 
Fig.2 shows a most probable linear sequence 
following the C-terminus of bradykinin moiety along 
the polypeptide chain of HMW kininogen. As pre- 
viously reported [7], the kinin-free kininogen, which 
consists of heavy and light chains bridged by a single 
disulfide bond and is devoid of bradykinin, fragment 
1 and fragment 2, constitutes the N- and C-terminal 
large portions of whole HMW kininogen. Thus, the 
three peptide fragments could be located in the por- 
tion between the heavy and the light chains. The 
order of these fragments along the polypeptide chain 
seems to be aligned as shown in Fig.2, because the 
N-terminal Ser-Val-Gln-Val-Met sequence of 
fragment 1 was the same as the C-terminal sequence 
of the CNBr-fragment (Lys-Arg-Pro-Gly-Phe- 
Ser-Pro-Phe-Arg-Ser-Val-Gln-Val-Met) con- 
taining kallidin [2] and because fragment l-2 with 
the N-terminal sequence of Ser-Val-Gln was an 
intermediate which is subsequently cleaved into 
fragment 1 and fragment 2 [lo]. The interesting 
features of the partial primary structure of HMW 
kininogen are that an unusual histidine-rich region, 
which contains approx. 70% out of the total histidine 
residues of the kininogen, is found in the sequences 
of fragment 1 and fragment 2, and that a repeating 
sequence with the type of His-Gly-X or Gly-His-X 
appears many times in such region. Further, the 
region contains a total of thirteen lysine and three 
arginine residues. Thus, the C-terminal portion 
following kinin moiety appears to be extremely basic 
and hydrophilic. 
Quite recently, a new function of HMW kininogen 
has been suggested by findings of Flaujeac [ 111, 
Fitzgerald [ 121 and Williams [ 131 traits with a 
deficiency of the kininogen. The deficient plasma 
does not release kinin upon incubation of kallikrein 
and also has a prolonged-activated partial thrombo- 
plastin time and inability to form plasmin. Of these 
kininogen deficient traits, bovine HMW kininogen used 
here corrects a prolonged-activated partial thrombo- 
plastin time on the.deficient plasma from Flaujeac 
trait but the kinin-free HMW kininogen is only 0.6% 
as effective as native HMW kininogen [ 141 . These 
observations strongly suggest hat the function of 
HMW kininogen is dependent upon the unusual 
histidine-rich polypeptide region with the total 110 
amino acid residues containing fragment 1 and frag- 
ment 2. Thus, some participation of the kallikrein 
fragments in the intrinsic blood coagulation and 
fibrinolysis, in addition to the kinin-forming system 
is now being suggested. 
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